How to access Adbry from the UAE — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A UAE adult or adolescent with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical therapies — or who has not responded adequately to a previous biologic — may receive a prescription for Adbry (tralokinumab; marketed as Adtralza outside the US) from their treating dermatologist. Adbry is FDA-approved, developed by LEO Pharma, and is a fully human monoclonal antibody that specifically binds IL-13 and neutralises its interaction with both IL-13 receptor alpha-1 and alpha-2. In the UAE, Adbry's local registration status varies and it may not be broadly available for every patient who clinically qualifies, which is why your dermatologist may be navigating a named-patient import pathway with you.
This guide explains the legal pathway, what your dermatologist needs to provide, typical timelines, and where Reserve Meds fits in.
The clinical situation
Adbry is administered subcutaneously. The labelled regimen for moderate-to-severe atopic dermatitis is a loading dose followed by maintenance every two weeks, with an option for every-four-weeks maintenance in selected patients who achieve clear or almost-clear skin at week 16. Eligibility is a clinical decision by your treating dermatologist based on disease severity, prior therapies, and response pattern. Adbry's IL-13-specific mechanism is distinct from dupilumab's IL-4Ra blockade, which is relevant when your dermatologist is selecting among type-2 pathway biologics.
Is Adbry legally importable into the UAE?
Yes — through the UAE Ministry of Health and Prevention (MoHAP) named-patient import framework.
The named-patient mechanism allows a UAE-licensed physician to request import of a medicine not locally registered or not locally available for a specific patient when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no locally available alternative is clinically equivalent for this patient, (c) the physician takes clinical responsibility, and (d) the importing party documents chain of custody. The MoHAP Drug Department reviews each application.
How the pathway works, step by step
- Consultation with your treating dermatologist. Clinical rationale documented, including severity assessment, prior therapies, and Adbry as the indicated therapy.
- Import License application. Your dermatologist or the importing pharmacy files an application with MoHAP including the clinical rationale, patient identification (de-identified where possible), product details, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
- Cold-chain shipment. Temperature-controlled transport with documented chain of custody.
- Arrival and administration. Subcutaneous administration per your dermatologist's protocol; most patients or caregivers self-inject at home after training.
- Ongoing coordination. Reserve Meds supports re-supply cadence aligned to every-two-weeks or every-four-weeks dosing.
What documentation your physician needs
Your dermatologist will typically need to provide:
- Clinical rationale letter confirming diagnosis, severity, prior therapies, and Adbry as the indicated therapy
- Verification of their UAE medical licence
- Patient identifier (anonymised reference where possible)
- Prescription with specified loading and maintenance dose
- Planned administration setting (home-injection or clinic)
Reserve Meds provides a physician documentation kit that bundles the templates MoHAP reviewers expect.
Costs and timing
Adbry's US cash-pay list price runs in an indicative 2026 range of roughly USD 3,200–3,800 per month at every-two-weeks maintenance, with the every-four-weeks schedule reducing monthly cost for eligible responders. Shipment, cold-chain logistics, and concierge coordination add incremental cost; Reserve Meds issues a transparent quote at the start of intake.
Indicative timeline — not guaranteed — for the first shipment after cohort intake opens is approximately 10–21 days from the moment a complete application is submitted to MoHAP. Re-supply is generally faster once the pathway is established.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Adbry specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory documentation package for your physician and for MoHAP review.
- Logistics. Cold-chain and temperature-monitored shipment coordination.
- Concierge case lead. A named point of contact throughout the coordination.
What we do not do: We are not the prescriber. We do not practice medicine. We are not the dispensing pharmacy. All clinical decisions remain with your treating dermatologist. We are in pre-launch and operate on a waitlist basis.
Frequently asked
Is this legal? Yes, when executed through the MoHAP named-patient framework. See our trust and compliance page.
How does Adbry compare with dupilumab? Adbry is IL-13-specific; dupilumab blocks the IL-4 receptor alpha, affecting both IL-4 and IL-13 signalling. The two are clinically distinct options; your dermatologist decides which is appropriate based on your history.
Can an adolescent receive Adbry? Adbry is labelled down to the adolescent age bands in the FDA label. Your dermatologist determines suitability.
Can I self-inject at home? After training by your clinical team, most patients or caregivers self-inject at home using the pre-filled syringe or pen presentation.
What about side effects? Common effects include upper respiratory infections, injection-site reactions, and conjunctivitis; your dermatologist manages monitoring and any adverse events.
Will insurance cover any of this? Cash-pay is the default for named-patient imports. Some UAE private insurers reimburse on case-by-case approval; we supply documentation for your submission.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Adbry coordination.
Add me to the Adbry waitlistComposite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.